Akt and c-Myc Induce Stem-Cell Markers in Mature Primary p53-/- Astrocytes and Render These Cells Gliomagenic in the Brain of Immunocompetent Mice

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Radke, Josefine ^a   Bortolussi, Ginette ^a   Pagenstecher, Axel ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROTEIN KINASE B; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL STRUCTURE; COCARCINOGENESIS; CONTROLLED STUDY; GLIOMA; IMMUNOLOGICAL TOLERANCE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; ASTROCYTES; BIOLOGICAL MARKERS; BRAIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOCOMPETENCE; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873721875     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056691     Document Type: Article

References (60)

1. CBTRUS (2012) (2012) Statistical Report: Primary Brain Tumors in the United States, 2004-2008: Central Brain Tumor Registry of the United States, 2012. Available: http://www.cbtrus.org/reports/reports.html.
2. Moliterno JA, Patel TR, Piepmeier JM, (2012) Neurosurgical approach. Cancer J 18: 20-25.
3. Weller M, Stupp R, Hegi M, Wick W, (2012) Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J 18: 40-44.
4. Huse JT, Holland EC, (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10: 319-331.
5. Ohgaki H, Kleihues P, (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453.
6. Park DM, Rich JN, (2009) Biology of glioma cancer stem cells. Mol Cells 28: 7-12.
7. Ohgaki H, Kleihues P, (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100: 2235-2241.
8. Purow B, Schiff D, (2009) Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol 5: 419-426.
9. Fischer U, Leidinger P, Keller A, Folarin A, Ketter R, et al. (2010) Amplicons on chromosome 12q13-21 in glioblastoma recurrences. Int J Cancer 126: 2594-2602.
10. Bogler O, Nagane M, Gillis J, Huang HJ, Cavenee WK, (1999) Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro. Cell Growth Differ 10: 73-86.
11. Yahanda AM, Bruner JM, Donehower LA, Morrison RS, (1995) Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol 15: 4249-4259.
12. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T, (2000) Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26: 109-113.
13. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, et al. (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25: 55-57.
14. Lassman AB, Dai C, Fuller GN, Vickers AJ, Holland EC, (2004) Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice. Neuron Glia Biol 1: 157-163.
15. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, et al. (2001) Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 61: 6674-6678.
16. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, et al. (2001) Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 61: 4956-4960.
17. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S, Wesseling P, (2007) RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 114: 121-133.
18. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, et al. (2008) Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb Symp Quant Biol 73: 427-437.
19. Boone DN, Qi Y, Li Z, Hann SR, (2011) Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci U S A 108: 632-637.
20. Felsher DW, Zetterberg A, Zhu J, Tlsty T, Bishop JM, (2000) Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci U S A 97: 10544-10548.
21. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, et al. (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A 106: 3207-3212.
22. Stalder AK, Pagenstecher A, Kincaid CL, Campbell IL, (1999) Analysis of Gene Expression by Multiprobe RNase Protection Assay. Methods Mol Med 22: 53-66.
23. Swift S, Lorens J, Achacoso P, Nolan GP, (2001) Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol Chapter 10: Unit 10 17C.
24. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, et al. (2007) Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129: 1065-1079.
25. Schmidt KF, Ziu M, Schmidt NO, Vaghasia P, Cargioli TG, et al. (2004) Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J Neurooncol 68: 207-215.
26. Friedl G, Hofer M, Auber B, Sauder C, Hausmann J, et al. (2004) Borna disease virus multiplication in mouse organotypic slice cultures is site-specifically inhibited by gamma interferon but not by interleukin-12. J Virol 78: 1212-1218.
27. Althoff GE, Wolfer DP, Timmesfeld N, Kanzler B, Schrewe H, et al. (2010) Long-term expression of tissue-inhibitor of matrix metalloproteinase-1 in the murine central nervous system does not alter the morphological and behavioral phenotype but alleviates the course of experimental allergic encephalomyelitis. Am J Pathol 177: 840-853.
28. Wildeboer D, Naus S, Amy Sang QX, Bartsch JW, Pagenstecher A, (2006) Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol 65: 516-527.
29. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, et al. (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68: 9703-9711.
30. Hambardzumyan D, Parada LF, Holland EC, Charest A, (2011) Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia 59: 1155-1168.
31. Siebzehnrubl FA, Reynolds BA, Vescovi A, Steindler DA, Deleyrolle LP, (2011) The origins of glioma: E Pluribus Unum? Glia 59: 1135-1147.
32. Varley JM, Evans DG, Birch JM, (1997) Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer 76: 1-14.
33. Kleihues P, Ohgaki H, (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1: 44-51.
34. Meletis K, Wirta V, Hede SM, Nister M, Lundeberg J, et al. (2006) p53 suppresses the self-renewal of adult neural stem cells. Development 133: 363-369.
35. Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, et al. (2009) Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell 15: 514-526.
36. Spalding KL, Bhardwaj RD, Buchholz BA, Druid H, Frisen J, (2005) Retrospective birth dating of cells in humans. Cell 122: 133-143.
37. Ge WP, Miyawaki A, Gage FH, Jan YN, Jan LY, (2012) Local generation of glia is a major astrocyte source in postnatal cortex. Nature 484: 376-380.
38. Bogler O, Huang HJ, Cavenee WK, (1995) Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res 55: 2746-2751.
39. Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, et al. (1999) Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro Oncol 1: 124-137.
40. Bello MJ, Rey JA, (2006) The p53/Mdm2/p14ARF cell cycle control pathway genes may be inactivated by genetic and epigenetic mechanisms in gliomas. Cancer Genet Cytogenet 164: 172-173.
41. Kim YH, Lachuer J, Mittelbronn M, Paulus W, Brokinkel B, et al. (2011) Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations. Brain Pathol 21: 645-651.
42. Wang Y, Wang X, Zhang J, Sun G, Luo H, et al. (2012) MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas. J Neurooncol 106: 217-224.
43. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, et al. (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455: 1129-1133.
44. Endersby R, Baker SJ, (2008) PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 27: 5416-5430.
45. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, et al. (2008) Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14: 447-457.
46. Herold S, Herkert B, Eilers M, (2009) Facilitating replication under stress: an oncogenic function of MYC? Nat Rev Cancer 9: 441-444.
47. Fatoo A, Nanaszko MJ, Allen BB, Mok CL, Bukanova EN, et al. (2011) Understanding the role of tumor stem cells in glioblastoma multiforme: a review article. J Neurooncol 103: 397-408.
48. Hoffman B, Liebermann DA, (2008) Apoptotic signaling by c-MYC. Oncogene 27: 6462-6472.
49. Martelli AM, Faenza I, Billi AM, Manzoli L, Evangelisti C, et al. (2006) Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell Signal 18: 1101-1107.
50. Ruano Y, Mollejo M, Camacho FI, Rodriguez de Lope A, Fiano C, et al. (2008) Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme. Cancer 112: 1575-1584.
51. Munoz DM, Guha A, (2011) Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas. Oncotarget 2: 590-598.
52. Hadjipanayis CG, Van Meir EG, (2009) Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med 15: 519-530.
53. Tabatabai G, Weller M, (2011) Glioblastoma stem cells. Cell Tissue Res 343: 459-465.
54. Ke RH, Xiong J, Liu Y, Ye ZR, (2009) Adenosine A2a receptor induced gliosis via Akt/NF-kappaB pathway in vitro. Neurosci Res 65: 280-285.
55. Bourseau-Guilmain E, Griveau A, Benoit JP, Garcion E, (2011) The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PLoS One 6: e25515.
56. Jao SW, Chen SF, Lin YS, Chang YC, Lee TY, et al. (2012) Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Ann Surg Oncol 19: 3432-3440.
57. Lee JS, Gil JE, Kim JH, Kim TK, Jin X, et al. (2008) Brain cancer stem-like cell genesis from p53-deficient mouse astrocytes by oncogenic Ras. Biochem Biophys Res Commun 365: 496-502.
58. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, et al. (2008) CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122: 761-768.
59. Vetter M, Hofer MJ, Roth E, Pircher HP, Pagenstecher A, (2009) Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma. J Neuropathol Exp Neurol 68: 525-534.
60. Ksendzovsky A, Feinstein D, Zengou R, Sharp A, Polak P, et al. (2009) Investigation of immunosuppressive mechanisms in a mouse glioma model. J Neurooncol 93: 107-114.